Author details

Full Name

Daniel E Bauer

Affiliation

ORCID

Career Start Year

1999

Papers

111

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37292647	Gene editing without <i>ex vivo</i> culture evades genotoxicity in human hematopoietic stem cells.	bioRxiv	2023
37651157	A viable alternative for editor delivery.		2023
37648862	Epitope editing enables targeted immunotherapy of acute myeloid leukaemia.	Nature	2023
36522432	Human genetic diversity alters off-target outcomes of therapeutic gene editing.		2023
36592307	Base Editing of Human Hematopoietic Stem Cells.		2023
36907603	Molecular Basis and Genetic Modifiers of Thalassemia.		2023
37273902	Pre-existing immunity does not impair the engraftment of CRISPR-Cas9-edited cells in rhesus macaques conditioned with busulfan or radiation.		2023
37208464	Gene correction for sickle cell disease hits its prime.		2023
37332392	Swapping the serotype: A novel helper-dependent adenoviral vector platform for HSC gene therapy.		2023
36639729	Therapeutic adenine base editing of human hematopoietic stem cells.		2023
36639728	Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing.		2023
37391485	RUNX1 mutations mitigate quiescence to promote transformation of hematopoietic progenitors in Fanconi anemia.		2023
37537351	Dictys: dynamic gene regulatory network dissects developmental continuum with single-cell multiomics.		2023
35167623	DNAJB1-PRKACA in HEK293T cells induces LINC00473 overexpression that depends on PKA signaling.	PLoS One	2022
35526095	Development of a double shmiR lentivirus effectively targeting both BCL11A and ZNF410 for enhanced induction of fetal hemoglobin to treat Î²-hemoglobinopathies.	Molecular Therapy	2022
36206729	Pervasive donor DNA integration defies precision gene editing of hematopoietic stem cells.		2022
36481753	Whole genome sequencing identifies structural variants contributing to hematologic traits in the NHLBI TOPMed program.	Nat Commun	2022
34344987	Targeting leukemia-specific dependence on the de novo purine synthesis pathway.	Leukemia	2022
34628053	Editing outside the body: ExÂ vivo gene-modification for Î²-hemoglobinopathy cellular therapy.	Molecular Therapy	2021
33859416	ZNF410 represses fetal globin by singular control of CHD4.	Nature Genetics	2021
33691767	Editing GWAS: experimental approaches to dissect and exploit disease-associated genetic variation.	Genome Medicine	2021
33532840	Motif-Raptor: a cell type-specific and transcription factor centric approach for post-GWAS prioritization of causal regulators.		2021
33731942	Author Correction: Transcription factor competition at the Î³-globin promoters controls hemoglobin switching.	Nat Genet	2021
33887194	Whole-genome sequencing association analysis of quantitative red blood cell phenotypes: The NHLBI TOPMed program.	Am J Hum Genet	2021
33938942	Molecular analysis of the erythroid phenotype of a patient with BCL11A haploinsufficiency.	Blood Adv	2021
33513358	Dissecting ELANE neutropenia pathogenicity by human HSC gene editing.	Cell Stem Cell	2021
34087167	Whole-genome sequencing association analysis of quantitative red blood cell phenotypes: The NHLBI TOPMed program.	Am J Hum Genet	2021
33649594	Transcription factor competition at the Î³-globin promoters controls hemoglobin switching.	Nat Genet	2021
34521115	Clonal hematopoiesis in sickle cell disease.	Blood	2021
32897878	BCL11A enhancer-edited hematopoietic stem cells persist in rhesus monkeys without toxicity.	J Clin Invest	2020
32433547	Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity.	Nat Biotechnol	2020
32433548	Author Correction: Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity.	Nat Biotechnol	2020
33230299	Common variants in signaling transcription-factor-binding sites drive phenotypic variability in red blood cell traits.	Nat Genet	2020
30991026	Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias.	Cancer Cell	2019
31624354	Production of foetal globin in adult monkeys.	Nature Biomedical Engineering	2019
31809537	End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings.	Blood Adv	2019
30355263	Emerging Genetic Therapy for Sickle Cell Disease.	Annu Rev Med	2019
30395160	DrugThatGene: integrative analysis to streamline the identification of druggable genes, pathways and protein complexes from CRISPR screens.		2019
30704988	Editing aberrant splice sites efficiently restores Î²-globin expression in Î²-thalassemia.	Blood	2019
30911135	Highly efficient therapeutic gene editing of human hematopoietic stem cells.	Nat Med	2019
31447068	Single-cell cloning of human T-cell lines reveals clonal variation in cell death responses to chemotherapeutics.	Cancer Genet	2019
31015418	Single-cell trajectories reconstruction, exploration and mapping of omics data with STREAM.	Nat Commun	2019
31253978	Rational targeting of a NuRD subcomplex guided by comprehensive in situ mutagenesis.	Nat Genet	2019
30992567	CRISPR-suppressor scanning reveals a nonenzymatic role of LSD1 in AML.	Nature Chemical Biology	2019
29193029	Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies.	Br J Haematol	2018
30504875	CRISPR-SURF: discovering regulatory elements by deconvolution of CRISPR tiling screen data.	Nat Methods	2018
30059493	An APOBEC3A-Cas9 base editor with minimized bystander and off-target activities.	Nat Biotechnol	2018
30340514	CRISPRO: identification of functional protein coding sequences based on genome editing dense mutagenesis.		2018
29958563	Genetic therapies for sickle cell disease.	Seminars in Hematology	2018
29949956	AmpUMI: design and analysis of unique molecular identifiers for deep amplicon sequencing.		2018